- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04450290
Dexamethasone-Eluting Cochlear Implant Electrode (CIDEX)
Dexamethasone-Eluting Cochlear Implant Electrode (CIDEXEL): A First in Human Study
A newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array. The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma.
The aim of this clinical investigation is to obtain a first experience in use of the investigational device in the adult clinical population, and to initially assess tools, techniques and performance outcome measures that may be considered in future clinical studies of similar devices.
Study Overview
Status
Intervention / Treatment
Detailed Description
The principal objective of this study is to exploratively investigate the safety profile of the device which will be evaluated through the analysis of adverse events during the follow-up period. For the study to be considered a success, the results of the adverse event analysis shall never cause an unbalanced risk vs. benefit assessment.
The secondary objectives of this study aim at investigating the usefulness of possible outcome measures in evaluating the performance of the device.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Hannover, Germany, 30625
- MHH - Medizinische Hochschule Hannover
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Minimum age of eighteen (18) years at time of enrolment.
- Severe to profound sensorineural hearing loss on the ipsilateral ear.
- A functional auditory nerve in the ear to be implanted.
- Subjects reporting to having used an optimally fit hearing aids for a minimum of three months before the decision that a cochlear implant (CI) is the preferential option.
- Cochlea anatomy compatible with the insertion of a +FLEX28 electrode array.
- Compatibility with a soft surgery approach as per clinical practice at the site.
- Post-lingual hearing impairment.
- Subject fulfilling indication criteria for a CI according to the local professional standards, as reported by the implanting surgeon.
- General health condition, psychological and emotional condition deemed compatible with the treatment and tests performed in this study and realistic expectations, as deemed appropriate by the implanting surgeon.
- Signed and dated informed consent before the start of any study-specific procedure.
Exclusion Criteria:
- Lack of compliance with any inclusion criterion.
- Previously having received a cochlear implant on the ear chosen for placing the IMD (Investigational Medical Device).
- Evidence of ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array or might cause increased risk of infection (e.g. dysplastic cochlea), as confirmed by medical examination and/or as per CT/MRT (Computed Tomography/Magnetic Resonance Tomography).
- Evidence of anatomic abnormalities that would prevent appropriate placement of the stimulator housing in the bone of the skull.
- Evidence of otosclerosis.
- Known allergic reaction or intolerance to the materials used in the implant (including medical grade silicone, platinum, iridium, parylene c, dexamethasone).
- Known absence of cochlear development or if the cause of deafness is non-functionality of the auditory nerve and/or the upper auditory pathway.
- Evidence of active external or middle ear infection or history of recurrent middle ear infection in the ear to be implanted.
- Evidence of perforated tympanic membrane in the ear to be implanted.
- Patient reporting immunosuppressive therapy or corticosteroids therapy in the 4 weeks before enrolment.
- Evidence of concomitant use of medicinal substances that, in the opinion of the investigator, could alter the therapeutic efficacy of dexamethasone.
- Unwillingness or inability of the candidate to comply with all investigational requirements.
- Evidence of medical contraindications to surgery of the middle and inner ear and anaesthesia.
- Additional disabilities that would prevent or restrict participation in the audiological and medical evaluations required of the clinical investigation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single arm - treatment
All subjects will be implanted with the investigational device.
|
The newly developed MED-EL Cochlear Implant incorporates the anti-inflammatory agent dexamethasone (DEX) into the electrode array.
The passive elution of DEX during the post-implantation period has the purpose of counteracting the increase of the post-operative impedance induced by the insertion trauma.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: 10 months
|
Safety profile of the device which will be evaluated through the analysis of adverse events
|
10 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
IFT (Impedance Field Telemetry) - impedance
Time Frame: 10 months
|
Impedance Field Telemetry and derived values
|
10 months
|
Electrically Evoked Compound Action Potential
Time Frame: 10 months
|
Electrically Evoked Compound Action Potential and derived values
|
10 months
|
MCL (Maximum Comfortable Loudness)
Time Frame: 10 months
|
Maximum Comfortable Loudness Levels and Thresholds
|
10 months
|
THR (Threshold)
Time Frame: 10 months
|
Thresholds
|
10 months
|
PTA (Pure Tone Audiometry) Audiometrical values
Time Frame: 10 months
|
Results from PTA assessment
|
10 months
|
Hearing Preservation rate
Time Frame: 10 months
|
Rate of Hearing Preservation according to Skarżyński et al.
|
10 months
|
HSM (Hochmair-Schulz-Moser Sentence) Test
Time Frame: 10 months
|
Speech test in noise
|
10 months
|
Questionnaire
Time Frame: 10 months
|
Surgical feedback questionnaire
|
10 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Thomas Lenarz, Prof. Prof. h. c. Dr. med., Hals-Nasen-Ohrenklinik der Medizinischen Hochschule Hannover
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MED-EL_CRD_2014_02
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sensorineural Hearing Loss
-
Oticon MedicalNot yet recruitingSensorineural Hearing Loss, Bilateral | Sensorineural Hearing Loss, Severe | Sensorineural Hearing Loss, Profound
-
Otologics LLCUnknownMixed Conductive and Sensorineural Hearing Loss, Bilateral
-
Fundación Pública Andaluza para la gestión de la...RecruitingBilateral Sensorineural Hearing Loss | Unilateral Sensorineural Hearing LossSpain
-
CochlearCompletedUnilateral Mixed Conductive and Sensorineural Hearing Loss (Diagnosis) | Sensorineural Hearing Loss, Unilateral With Normal Hearing on the Contralateral SideCanada
-
University College, LondonUnknownSensorineural Hearing Loss | Sensory Hearing Loss | Sensorineural Hearing Loss in Left Ear | Sensorineural Hearing Loss in Right Ear | Sensorineural HearingUnited Kingdom
-
University Hospital, AntwerpCochlearRecruitingHearing Loss, Unilateral | Cochlear Implants | Hearing Loss, Sensorineural, Severe | Hearing Loss, Sensorineural, Bilateral | Hearing Loss, Sensorineural, ProfoundBelgium
-
Auris Medical, Inc.TerminatedHearing Loss, Idiopathic Sudden SensorineuralUnited States, Korea, Republic of, Canada
-
Manchester University NHS Foundation TrustUniversity of ManchesterCompletedCochlear Hearing Loss | Sensorineural Hearing Loss, BilateralUnited Kingdom
-
Cochlear Bone Anchored SolutionsCompletedSingle Sided Sensorineural Deafness | Mixed Hearing Loss, UnilateralDenmark, Spain, United Kingdom, Belgium
-
University of Colorado, DenverCompletedSudden Sensorineural Hearing Loss (SSNHL)United States
Clinical Trials on CIDEXEL implant
-
Aula Dental AvanzadaRecruiting
-
University of Sao PauloCompletedCataract | AstigmatismBrazil
-
Aula Dental AvanzadaCompleted
-
Mentor Worldwide, LLCWithdrawnAugmentation | Augmentation Revision | General Breast Enlargement | Post-lactational Involution | AsymmetryUnited States
-
ZimVieCompletedPartial Edentulism | Tooth DiseaseUnited States
-
Ideal Implant IncorporatedCompletedBreast ImplantsUnited States
-
University of BernNot yet recruitingComplications | Patient Reported Outcome Measures | Cost-Benefit Analysis | Cost-effectiveness | Esthetic Zone | Single Tooth Dental Implant | Single Tooth Lost | Accuracy of Dental Implants | Dimensional Changes | Implant Survival and Success | Frequency of Treatment ProtocolSwitzerland
-
Cairo UniversityNot yet recruitingEdentulous; Alveolar Process, Atrophy
-
Cairo UniversityCompletedAtrophic Maxillary Ridge and Mandibular RidgeEgypt
-
ARDEC AcademyCompletedEdentulous; Alveolar Process, AtrophyColombia